Brilacidin for certain is worth $1B in my mind.
Post# of 72440
Prurisol will hopefully be worth that if it matches the phase 2a 200mg PP moderate cases in the phase 2b using 300mg. Just repeating the PP moderate of the 200mg with 80 patients would be stellar.
Kevetrin I'm not so sure of. Depends how good or bad things actually are with regard to the results of the recently ended phase 2a. I don't think we have enough info to come to a conclusion yet. Certainly not to put a $1B price tag on it.
Agreed on the share price - we should be in the $2-$5 range right now. With good P results bump that up significantly. On a deal with a proper upfront ($30M+) and phase 3 costs covered we could go to $10.
Just my opinion.
Go IPIX!